{"contentid": 488774, "importid": NaN, "name": "Fourth COVID-19 vaccine jab gets conditional OK in UK", "introduction": "The UK\u00e2\u0080\u0099s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted conditional marketing authorization for a fourth novel coronavirus vaccine, and the first given as a single-dose vaccine, that has been developed by the Janssen unit of US healthcare giant Johnson & Johnson.", "content": "<p>The UK&rsquo;s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted conditional marketing authorization for a fourth novel coronavirus vaccine, and the first given as a single-dose vaccine, that has been developed by the Janssen unit of US healthcare giant Johnson &amp; Johnson (NYSE: JNJ).</p>\n<p>COVID-19 Vaccine Janssen is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. &nbsp;</p>\n<p>The UK government has secured 20 million doses of the vaccine for use across the UK, which are expected to be available from later this year.</p>\n<h2><strong>Clinical backing</strong></h2>\n<p>Data from the Phase III ENSEMBLE study evaluated efficacy and safety of COVID-19 Vaccine Janssen in preventing moderate to severe (symptomatic) COVID-19 in individuals 18 years and older, with co-primary endpoints of 14 days and 28 days following vaccination. The data from the primary efficacy analysis showed that COVID-19 Vaccine Janssen was generally well tolerated and demonstrated 67% reduction (95% CI: 59%&ndash;73%) in symptomatic COVID-19 disease 14 days after vaccination, and similar results were seen from 28 days after vaccination, in participants who received the vaccine in comparison to participants given the placebo.</p>\n<p>The data also demonstrated the vaccine was 85 percent effective (95 percent CI: 54%&ndash;97%) in preventing severe disease across all regions studied and showed reduction of COVID-19 related hospitalization from 14 days after vaccination.<sup>1</sup>&nbsp;</p>\n<p>&ldquo;The MHRA authorization of our single-dose COVID-19 vaccine marks another important step forward in the global effort to end the COVID-19 pandemic,&rdquo; says Dr Mohamed Lockhat, medical director, Infectious Diseases &amp; Vaccines at Janssen UK.</p>\n<p>As with AstraZeneca&rsquo;s (LSE: AZN) Vaxzevria, Johnson &amp; Johnson will make COVID-19 Vaccine Janssen available on a not-for-profit basis for emergency pandemic use. The conditional approval permits the supply and use of COVID-19 Vaccine Janssen in Great Britain while more data are gathered and while the company files for a full license with the MHRA.</p>\n<p>&nbsp;</p>", "date": "2021-05-28 14:01:00", "meta_title": "Fourth COVID-19 vaccine jab gets conditional OK in UK", "meta_keywords": "Janssen, Johnson & Johnson, COVID-19 Vaccine, Approval, Conditional, MHRA", "meta_description": "Fourth COVID-19 vaccine jab gets conditional OK in UK", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-28 14:00:50", "updated": "2021-05-28 14:06:44", "access": NaN, "url": "https://www.thepharmaletter.com/article/fourth-covid-19-vaccine-jab-gets-conditional-ok-in-uk", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "mhra_large.png", "image2id": "mhra_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "COVID-19 vaccines", "sector_tag": NaN, "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Focus On, Medicines and Healthcare products Regulatory Agency (MHRA), Regulation", "geography_tag": "UK", "company_tag": "Janssen, Johnson & Johnson", "drug_tag": "COVID-19 Vaccine Janssen", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-28 14:01:00"}